Tag Archives: biotechnology

Universities Response to Patent “Reform” Legislation

Posted on February 27, 2015 by Warren Woessner

On February 24th, a letter sent by the Association of American Universities, signed by 145 universities, to Senators Grassley and Leahy and Representatives Goodlatte and Conyers, objected to parts of legislation such as “The Innovation Act, H.R. 9” that purports … Continue reading →

Posted in Patent Reform Legislation | Tagged , , , , , , , | 1 Comment

“Precision Medicine” Initiative Leaves Patents “Lost in Space”

Posted on February 18, 2015 by Warren Woessner

On January 30th, the White House released a press release expanding upon President Obama’s mention of “precision medicine” in his State of the Union Address. Not surprisingly, the details are pretty much what we who are involved in various aspects … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , | Leave a comment

Section 101 at the AIPLA Midwinter Meeting

Posted on February 2, 2015 by Warren Woessner

Although the primary focus of this four day meeting was licensing, there were two simultaneous tracks that contained at least a section of the effect/uncertainty of the recent judicial decisions and PTO Guidelines on licensor/licensee relationships. (I spoke at one … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , | Leave a comment

Myriad Settles – Questions Remain

Posted on January 27, 2015 by Warren Woessner

Yesterday, Myriad announced it has settled the BRCA assay litigations that had been ongoing—and not going well– with Pathway Genomics, Invitae and Gene by Gene (and I assume….Ambry and Labcorp). Although I was just about at the brink of shouting … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment